Literature DB >> 10942407

Molecular heterogeneity of the Jk(null) phenotype: expression analysis of the Jk(S291P) mutation found in Finns.

F Sidoux-Walter1, N Lucien, R Nissinen, P Sistonen, S Henry, J Moulds, J P Cartron, P Bailly.   

Abstract

Polymerase chain reaction genotyping of 32 unrelated Jk(null) individuals originating predominantly from Polynesia and Finland indicated that all were homozygous for the JK*B polymorphism and that 17 of 32, including the 14 Polynesians, carried a 3'-acceptor splice site mutation of intron 5 that resulted in the skipping of exon 6 (called mutation Jk delta 6). The remaining 15 Jk(null) donors from Finland were homozygous for a new T871C transition resulting in a S291P amino acid substitution at a consensus N-glycosylation site of the Jk polypeptide. Transcription-translation assays revealed that the Jk(S291P) mutant was translated into a glycosylated component as efficiently as the wild-type Jk polypeptide (wt Jk)] in the presence of microsomes, thus indicating that the S291P mutation has no effect on the N-glycosylation pattern of the Jk protein. Expression studies in Xenopus oocytes revealed that the Jk(S291P) polypeptide functions as a urea transporter, but the transport activity and the membrane expression level of the mutant protein was reduced to a similar extent. A substantial fraction of the mutant protein was retained intracellularly suggesting that the transit to the plasma membrane was reduced, presumably because of the S-->P mutation. After transfection in erythroleukemia K562 cells the wild-type, but not the mutant, protein was efficiently expressed at the cell surface. Because the Jk(S291P) mutant polypeptide was not present in human red cells from Jk(null) individuals, expression data in the erythroid context clearly indicates that the S-->P mutation is the molecular basis of the Finnish Jk(null) phenotype. (Blood. 2000;96:1566-1573)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10942407

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  5 in total

Review 1.  The emerging physiological roles of the SLC14A family of urea transporters.

Authors:  Gavin Stewart
Journal:  Br J Pharmacol       Date:  2011-12       Impact factor: 8.739

2.  A rare case of anti-jk3 antibody detected on pre-transfusion investigation.

Authors:  Rabeya Yousuf; Suria Abdul Aziz; Nurasyikin Yusof; Chooi-Fun Leong
Journal:  Indian J Hematol Blood Transfus       Date:  2012-11-20       Impact factor: 0.900

3.  When recombinant proteins can replace rare red cells in immunohematology workups.

Authors:  Willy A Flegel; Kshitij Srivastava
Journal:  Transfusion       Date:  2021-05-31       Impact factor: 3.337

4.  Stabilization of Transfected Cells Expressing Low-Incidence Blood Group Antigens: Novel Methods Facilitating Their Use as Reagent-Cells.

Authors:  Cecilia González; Rosa Esteban; Carme Canals; Eduardo Muñiz-Díaz; Núria Nogués
Journal:  PLoS One       Date:  2016-09-07       Impact factor: 3.240

Review 5.  SLC14A1: a novel target for human urothelial cancer.

Authors:  R Hou; X Kong; B Yang; Y Xie; G Chen
Journal:  Clin Transl Oncol       Date:  2017-06-06       Impact factor: 3.405

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.